Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $0.77 down -4.90% from its previous closing price of $0.81. In other words, the price has decreased by -$4.90 from its previous closing price. On the day, 41.79 million shares were traded. DNA stock price reached its highest trading level at $0.83 during the session, while it also had its lowest trading level at $0.755.
Ratios:
For a deeper understanding of Ginkgo Bioworks Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.34 and its Current Ratio is at 5.34. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.24.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 16 ’24 when DEKKERS MARIJN E sold 265,000 shares for $0.83 per share. The transaction valued at 220,030 led to the insider holds 5,515,364 shares of the business.
Sankar Shyam bought 625,000 shares of DNA for $514,750 on May 15 ’24. The Director now owns 2,356,874 shares after completing the transaction at $0.82 per share. On May 14 ’24, another insider, SLOAN HARRY, who serves as the Director of the company, bought 297,619 shares for $0.91 each. As a result, the insider paid 271,815 and bolstered with 718,540 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 1694061440 and an Enterprise Value of 1088116992. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.68 while its Price-to-Book (P/B) ratio in mrq is 1.48. Its current Enterprise Value per Revenue stands at 5.214 whereas that against EBITDA is -1.725.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $2.55, while it has fallen to a 52-week low of $0.72. The 50-Day Moving Average of the stock is -22.90%, while the 200-Day Moving Average is calculated to be -46.49%.
Shares Statistics:
For the past three months, DNA has traded an average of 35.93M shares per day and 59342450 over the past ten days. A total of 1.53B shares are outstanding, with a floating share count of 1.39B. Insiders hold about 33.26% of the company’s shares, while institutions hold 58.21% stake in the company. Shares short for DNA as of 1714435200 were 289725988 with a Short Ratio of 8.06, compared to 1711584000 on 270825651. Therefore, it implies a Short% of Shares Outstanding of 289725988 and a Short% of Float of 23.68.
